Suzuki Y, et al. - In advanced biliary tract cancer (BTC) patients receiving gemcitabine plus cisplatin (GC) therapy, researchers identified prognostic factors of the overall survival (OS) via retrospectively reviewing data of 307 subjects with advanced BTC who received GC therapy as the first-line chemotherapy at their institution from January 2007 to June 2017. Independent unfavorable prognostic factors are poor performance status, elevated serum lactate dehydrogenase, and elevated neutrophil-to-lymphocyte ratio, according to multivariate analysis, and OS differs significantly among the three groups.